Physician profile
Ruby E Kassanoff
NPI 1467464594
$1,875.85
in general payments reported to CMS, 2019-2025
31 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $201 · 2021: $187 · 2022: $75.10 · 2023: $81.65 · 2024: $212 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $607.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $231.65 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amarin Pharma, INC. | $214.83 | 2019-2021 | |
| Abbvie INC. | $204.13 | 2019-2024 | |
| Amgen INC. | $201.30 | 2019-2025 | Evenity, Otezla, Repatha |
| Abbott Laboratories | $175.53 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $110.52 | 2019-2023 | Veozah |
| Glaxosmithkline, LLC. | $80.46 | 2019-2025 | Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $65.11 | 2025 | Gemtesa |
| Astrazeneca Pharmaceuticals Lp | $61.04 | 2019-2020 | |
| Lilly USA, LLC | $46.89 | 2019-2020 | |
| Pfizer INC. | $45.02 | 2019-2023 | |
| Itamar Medical INC | $43.74 | 2022 | |
| Gilead Sciences, INC. | $42.79 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.41 | 2019-2025 | Ofev |
| Janssen Pharmaceuticals, INC | $35.90 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cleerly, INC. | $32.83 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Regeneron Healthcare Solutions, INC. | $26.67 | 2019 | |
| Medtronic, INC. | $24.09 | 2025 | Symplicity G3 |
| Eisai INC. | $22.56 | 2020 | |
| Ethicon US, LLC | $18.41 | 2019 | |
| Verity Pharmaceuticals INC. | $18.26 | 2025 | Tlando |
| Avion Pharmaceuticals | $16.03 | 2021 | |
| Allergan, INC. | $14.39 | 2020 | |
| Ironwood Pharmaceuticals, INC | $14.25 | 2019 | |
| Ge Healthcare | $14.02 | 2019 | |
| Sanofi Pasteur INC. | $13.74 | 2019 | |
| Genentech USA, INC. | $13.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.11 | 2019 | |
| Merck Sharp & Dohme LLC | $13.10 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.98 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Kassanoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.